Document Detail


The long-term outcome of patients with polycystic liver disease treated with lanreotide.
MedLine Citation:
PMID:  22111942     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background  Polycystic liver disease (PLD) is a phenotypical expression of autosomal dominant polycystic kidney disease and isolated polycystic liver disease. Somatostatin analogues, such as lanreotide, reduce polycystic liver volume. Aim  To establish long-term outcome and safety of lanreotide. Methods  This was an open-label, observational extension study of a 6-month, randomised, placebo-controlled trial with lanreotide (120 mg/month) in PLD. The length of total treatment was 12 months. Primary endpoint was relative change in liver volume, as determined by CT-volumetry after 12 months of treatment. We offered patients a CT scan 6 months after stopping lanreotide. Results  A total of 41/54 (76%) patients participated in the extension study. Liver volume decreased by 4% (IQR -8% to -1%) after 12 months of treatment. The greatest effect was observed during the first 6 months of treatment (decrease of 4% (IQR -6% to -1%)). Liver volume remained unchanged during the following 6 months. We found that liver volume increased by 4% (IQR 0-6%) 6 months after end of treatment (n = 22). Conclusions  Lanreotide reduces liver volume within the first 6 months of treatment and the beneficial effect is maintained in the following 6 months. Stopping results in recurrence of polycystic liver growth. This suggests that continuous use of lanreotide is needed to maintain its effect.
Authors:
M Chrispijn; F Nevens; T J G Gevers; R Vanslembrouck; M G H van Oijen; W Coudyzer; A L Hoffmann; H M Dekker; R A de Man; L van Keimpema; J P H Drenth
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-11-24
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  -     ISSN:  1365-2036     ISO Abbreviation:  -     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2011 Blackwell Publishing Ltd.
Affiliation:
Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. Department of Hepatology, University Hospital Gasthuisberg, KULeuven, Belgium. Department of Radiology, University Hospital Gasthuisberg, KULeuven, Belgium. Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands. Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. Department of Gastroenterology and Hepatology, Erasmus Medical Centre, Rotterdam, the Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.
Next Document:  Vitality and the course of limitations in activities in osteoarthritis of the hip or knee.